Researchers at the University of Kentucky report that the brain's own immune cells, called microglia, may be a major cause of the sleep disruption seen in Alzheimer's. In a study published in Alzheimer's & Dementia, a team led by Shannon L. Macauley, Ph.D., and first author Nicholas J. Constantino, Ph.D., found that when most of these cells were temporarily removed from mice with Alzheimer's-like pathology, the animals slept longer and spent more time in deep, restorative NREM sleep.
The team's reasoning was that sleep problems in Alzheimer's had mostly been blamed on damaged neurons or on amyloid plaques themselves. Their data pointed elsewhere. Microglia normally clear debris and protect neurons, but when they encounter plaques their response can become excessive, releasing inflammatory signals that interfere with brain activity. Macauley compared this to a sprinkler system that floods an entire house when only one room is on fire.
The experiments compared genetically modified mice that develop plaques with normal mice at six and 18 months of age. Sleep was measured with EEG and EMG, and the brain's plaque and microglia distribution was mapped with light-sheet microscopy. To deplete microglia, the researchers fed the mice a drug called Pexidartinib (PLX3397), originally developed for cancer research, which removed about 87% of the cells after 14 days.
One unexpected result was that sleep disruption appeared early and did not worsen as plaques roughly doubled between six and 18 months. The study also found that normal aging mainly reduced REM sleep, while Alzheimer's pathology selectively disrupted NREM sleep, the stage linked to physical repair and clearing metabolic waste. The authors suspect a cycle in which poor sleep and disease feed each other.
For patients and caregivers, the work reframes sleep loss as something that may be driven by the immune response rather than only by plaque burden. Still, these findings come from mice, and the researchers stated that the same benefits have not been shown in people. Removing most of the brain's immune cells is not an established treatment, and the team is now asking whether adjusting microglial activity, rather than eliminating the cells, could produce similar effects.